Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Reports that Activ has recommended its SNG001 anti-viral lung treatment to progress to stage 3 trials in mild to moderate Covid-19 patients. Activ is a public-private partnership designed to co-ordinate research to develop Covid-19 treatments and vaccines. To date, the company has not received any data from the Activ-2 trial. However, the company says it own phase 3 Sprinter study of SNG001 in hospitalised Covid-19 patients is progressing well, with top-end results expected in early 2022.
"Data to date suggests SNG001 is well tolerated with a favourable safety profile and there is growing evidence to support the rationale for delivering IFN-beta directly into the lungs to counter the effects of SARS-CoV-2," says Chief Scientific Officer Phillip Monk.
Current stock price: 165.99 pence, up 13% on Wednesday morning
Year-to-date change: up 8.5%
By Scarlett Butler; scarlettbutler@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Synairgen (SNG)